New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
07:42 EDTINSM, IART, PBTH, AHS, CPHD, BIOS, ARNA, CLDX, USPH, DXCMOppenheimer to host a conference
23rd Annual Healthcare Conference is being held in New York on December 12-13 with webcasted presentations to begin on December 12 at 7:45 am; not all company presentations may be webcasted. Webcast Link
News For AHS;DXCM;ARNA;PBTH;USPH;BIOS;IART;CLDX;CPHD;INSM From The Last 14 Days
Check below for free stories on AHS;DXCM;ARNA;PBTH;USPH;BIOS;IART;CLDX;CPHD;INSM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
14:21 EDTINSMInsmed price target raised to $51 from $45 at Piper Jaffray
Piper Jaffray increased its price target on Insmed after meeting with the company's management, as the firm thinks the company's NTM will be approved. The firm keeps an Overweight rating on the stock.
11:16 EDTIARTIntegra LifeSciences initiated with a Buy at Lake Street
Subscribe for More Information
April 21, 2014
15:10 EDTINSMInsmed management to meet with Piper Jaffray
Meeting to be held in New York on April 22 hosted by Piper Jaffray.
April 17, 2014
17:39 EDTCPHDCepheid sees Q2 revenue $113M-$115M, consensus $110.68M.
Subscribe for More Information
16:10 EDTCPHDCepheid sees FY14 non-GAAP EPS 19c-24c, may not compare with consensus (24c)
Sees FY14 revenue in the range of $446M-$461M. Sees FY14 net loss in a range from $(0.43) to $(0.38) per share. Expected non-GAAP net income excludes approximately $33M related to stock compensation expense, approximately $9M related to the amortization of debt discount and debt issuance costs, and approximately $3M related to the amortization of acquired intangibles.
16:07 EDTCPHDCepheid reports Q1 non-GAAP EPS (1c), may not compare with consensus (17c)
Subscribe for More Information
15:29 EDTCPHDNotable companies reporting after market close
Notable companies reporting before tomorrow's market open, with earnings consensus, include athenahealth (ATHN), consensus 17c; Allison Transmission (ALSN), consensus 31c; Investors Bancorp (ISBC), consensus 24c; Cepheid (CPHD), consensus (17c); Advanced Micro Devices (AMD), consensus 0c; Associated Banc-Corp (ASBC), consensus 25c; Hub Group (HUBG), consensus 36c; Capital Bank (CBF), consensus 24c; Select Comfort (SCSS), consensus 32c; Acacia Research (ACTG), consensus 4c.
April 16, 2014
14:02 EDTCLDXCelldex Phase 1 study of CDX-1401 demonstrates robust antibody response
Subscribe for More Information
April 15, 2014
09:23 EDTIARTBarclays medical supplies/devices analysts hold analyst/industry conference call
Subscribe for More Information
08:19 EDTCLDXLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 10, 2014
16:58 EDTINSMJames Flynn reports 7.75% passive stake in Insmed
10:00 EDTDXCMOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:50 EDTDXCMDexCom upgraded at Sterne Agee
As noted earlier, Sterne Agee upgraded DexCom to Buy from Neutral. The firm expects the company to generate strong annual revenue growth, and believes that use of its G4 Platinum product will become more widespread after the FDA approved it for people ages 2-17. Target $50.
07:03 EDTCPHDCepheid announces European release of Xpert Norovirus
Cepheid announced the release of Xpert Norovirus, a qualitative in vitro diagnostic test for rapid identification and differentiation of Noroviruses genogroup I and genogroup II, to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on Cepheid's GeneXpert System.
05:54 EDTDXCMDexCom upgraded to Buy from Neutral at Sterne Agee
Price target is $50.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use